Clinical Development of NurOwn®

BrainStorm is proceeding with a randomized, double-blind, placebo-controlled multi-dose Phase 3 trial that will be conducted at multiple sites.

Additional information on the NurOwn® clinical trial development program can be found Here .

Please see link to the Northeast ALS Consortium (NEALS) Webinar entitled NurOwn® Clinical Development Program.

For additional information on enrollment in the NurOwn® phase 3 trial contact one of the clinical trial sites for details and screening.

Information is posted on clinicaltrials.gov .

 

We have undertaken three clinical trials in ALS to date

In all three trials, the primary endpoints were the safety and tolerability of a single intramuscular, intrathecal or simultaneous intramuscular and intrathecal administration. Key secondary efficacy endpoints included the rate of change in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and in forced vital capacity (FVC) during the post-treatment period compared to a three month pre-treatment run-in period.

View our available results from these studies.